P46 Patterns of recurrence and prognosis in women with basal-like breast cancer

Dent, R; Trudeau, M.; Pritchard, K.; Hanna, Wahid T.; Kahn, Harriette J.; Sawka, C.; Lickley, Lavina; Sun, Pei; Narod, S.A

doi:10.1016/s0960-9776(07)70111-x

Cited by 28 publications

(31 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Accounting for other known prognostic factors, it has been previously reported that TNBCs exhibit a distinctive early pattern of recurrence, peaking at 2-3 years, with the majority occurring within the first 5 years [44]. Therefore, the followup periods in the majority of the included studies in the present review are likely adequate to determine their intended survival endpoints.…”

Section: Discussionmentioning

confidence: 94%

The value of adjuvant radiotherapy on survival and recurrence in triple-negative breast cancer: A systematic review and meta-analysis of 5507 patients

O’Rorke

Murray

Brand

et al. 2016

Cancer Treatment Reviews

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 94%

The value of adjuvant radiotherapy on survival and recurrence in triple-negative breast cancer: A systematic review and meta-analysis of 5507 patients

O’Rorke

Murray

Brand

et al. 2016

Cancer Treatment Reviews

View full text Add to dashboard Cite

show abstract

“…One important bias of this study might be than more than 80% of the 542 patients were diagnosed with locally advanced (stage IIIA and IIIB) or metastatic disease (IV). In the adjuvant setting, there are studies published that show that triple negative tumors are associated with increased LRR [25] or with distant metastases [26,27]. An univariate analysis for all the variables comparing survival curves were performed and we didn't find any differences in locoregional disease control regarding hormonal receptors status nor Her-2-neu overexpression after NAC and breast conserving surgery.…”

Section: Accepted Manuscriptmentioning

confidence: 90%

Can we predict local recurrence in breast conserving surgery after neoadjuvant chemotherapy?

Cebrecos

Córdoba

Deu

et al. 2010

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

International audienceOne of the benefits of neoadjuvant chemotherapy (NAC) is its ability to convert patients ineligible for breast conservative treatment (BCT) to be candidates for this treatment, although questions have been raised regarding the effectiveness of BCT in terms of loco-regional recurrence (LRR). The objective of this study is to evaluate LRR in this group and the influence of tumor characteristics in recurrence

show abstract

“…TNBC disproportionately affects premenopausal women of African or Hispanic ancestry and progresses aggressively, accounting for 15-20% of breast cancer cases and 25% of deaths. 3,4 Although TNBC is sensitive to chemotherapy, the overall prognosis for TNBC patients is worse than for non-TNBC sub-types: TNBC tumors are frequently larger and less differentiated 5,6 and 2.5-fold more likely to metastasize. 4 TNBC patients also have a shorter median time to death (4.2 vs. 6 years) and poorer overall survival rates compared to other breast cancer subtypes.…”

Section: Introductionmentioning

confidence: 99%

Discovery and Characterization of Peptide Inhibitors for Calcium and Integrin Binding Protein 1

et al. 2020

View full text Add to dashboard Cite

Calcium and integrin binding protein 1 (CIB1) is an EF-hand-containing, small intracellular protein that has recently been implicated in cancer cell survival and proliferation. In particular, CIB1 depletion significantly impairs tumor growth in triple-negative breast cancer (TNBC). Thus, CIB1 is a potentially attractive target for cancer chemotherapy that has yet to be validated by a chemical probe. To produce a probe molecule to the CIB1 helix 10 (H10) pocket and demonstrate that it is a viable target for molecular intervention, we employed random peptide phage display to screen and select CIB1-binding peptides. The top peptide sequence selected, UNC10245092, was produced synthetically and binding to CIB1 was confirmed by isothermal titration calorimetry (ITC) and a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. Both assays showed that the peptide bound to CIB1 with low nanomolar affinity. CIB1 was co-crystallized with UNC10245092, and the 2.1 Å resolution structure revealed that the peptide binds as an αhelix in the H10 pocket, displacing the CIB1 C-terminal H10 helix and causing conformational changes in H7 and H8. UNC10245092 was further derivatized with a C-terminal Tat-derived cell penetrating peptide (CPP) to demonstrate its effects on TNBC cells in culture, which are consistent with results of CIB1 depletion. These studies provide a first-in-class chemical tool for CIB1 inhibition in cell culture and validate the CIB1 H10 pocket for future probe and drug discovery efforts.

show abstract

P46 Patterns of recurrence and prognosis in women with basal-like breast cancer

Cited by 28 publications

References 0 publications

The value of adjuvant radiotherapy on survival and recurrence in triple-negative breast cancer: A systematic review and meta-analysis of 5507 patients

The value of adjuvant radiotherapy on survival and recurrence in triple-negative breast cancer: A systematic review and meta-analysis of 5507 patients

Can we predict local recurrence in breast conserving surgery after neoadjuvant chemotherapy?

Discovery and Characterization of Peptide Inhibitors for Calcium and Integrin Binding Protein 1

Contact Info

Product

Resources

About